Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Not one, but two positive news items out today

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 24, 2023 9:23am

84 Views

Post# 35697908

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Not one, but two positive news items out today

Unfortunately some have decided to distract away from the fact that the IRA has provisioned for the FDA to grant novel biologics 13 years of market exclusivity from the date of product marketing approval. Also ONCY 's patents are extendable until the years 2031 / 2032 and will not impact on the FDA's 13 years of market exclusivity, which would be applied to any drug combinations containing pelareorep, thus giving off patent or soon to be off patent drugs like pembrolizumab, the same degree of 13 years exclusivity as applied to pelareorep.

<< Previous

Bullboard Posts

Next >>

98% energy efficiency: How Acceleware's EM Technology is transforming heat solutions